Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

GLSINYSE / NASDAQHealthcareSmall cap

$19.25-$0.54 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$347.1M
P/E
-22.0x
Revenue
$0.00
ROCE
-631.9%

+135.9% over the last year

Greenwich LifeSciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+18.5%
3M
+25.7%
6M
-29.5%
1Y
+135.9%
5Y
-44.7%

52-week range

Day change -$0.54 (-2.7%) from $20 to $19 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in GLSI, bought on each weekday since 2021.

News & filings

What Greenwich LifeSciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 15.8 million US dollars in fiscal 2024.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.00.
  • The latest financial year on file is fiscal 2024, which ended more than eighteen months before the latest prices.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2024

Rule-based from financial data. Not advice.

About the company

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Read moreShow less

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Sector
Healthcare
Shares outstanding
13.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$347.1M
P/E
-22.0x
P/B
137.0x
52-week high
$33.56
52-week low
$7.85

Profitability

ROE
-623.1%
ROCE
-631.9%
ROA
-385.7%

Growth

Revenue
$0.00
Net profit growth, 1Y
77.6%
Free cash flow
-$7.3M

Solvency

Current ratio
2.62
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.46
Cash / Market cap
1.2%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Greenwich LifeSciences, Inc. revenue and net profit by fiscal year
Greenwich LifeSciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2021$0.00-$4.6M
FY2022$0.00-$7.8M
FY2023$0.00-$8.9M
FY2024$0.00-$15.8M

Cash flows

FY2024: -$7.3M from operations, -$7.3M free after investment (dashed).

Greenwich LifeSciences, Inc. operating and free cash flow by fiscal year
Greenwich LifeSciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2021-$4.3M-$4.3M
FY2022-$6.2M-$6.2M
FY2023-$6.5M-$6.5M
FY2024-$7.3M-$7.3M

Growth

Latest fiscal year 2024: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$16.0M
Net profit
-$15.8M
Cash from operations
-$7.3M
Free cash flow
-$7.3M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2024$0.00-$16.0M-$15.8M-$7.3M-623.1%—+77.6%

Monthly returns

Month-by-month returns of GLSI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2024.

LineFY2024
Assets$4.1M
Liabilities$1.6M
Non-current liabilities$0.00
Equity$2.5M
Paid-in capital$68.7M
Retained earnings-$66.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; GLSI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Greenwich LifeSciences, Inc., Atea Pharmaceuticals, Inc., Larimar Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Greenwich LifeSciences, Inc.GLSIthis company$347.1M-22.0x137.0x-623.1%—
Puma Biotechnology, Inc.PBYI$356.8M11.5x2.7x23.9%6.7x
REGENXBIO Inc.RGNX$355.7M-1.8x3.5x-188.7%-3.0x
Atea Pharmaceuticals, Inc.AVIR$353.7M-2.2x1.3x-57.5%-1.4x
Larimar Therapeutics, Inc.LRMR$341.8M—4.4x-212.2%—
Enanta Pharmaceuticals, Inc.ENTA$341.1M-4.2x5.3x-126.5%-5.1x
Verastem, Inc.VSTM$339.2M-1.6x5.9x-366.2%-1.1x
Simulations Plus, Inc.SLP$336.4M-5.2x2.7x-51.9%20.8x
908 Devices Inc.MASS$333.5M17.1x2.3x13.6%-12.6x
Peer median—-1.8x3.1x-92.0%-1.4x

Year-to-date ROI

GLSI since 1 January, against earlier years.

Historical volatility

GLSI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2024
Operating expensesOperating Expense$16.0M
Research and developmentResearch And Development$12.9M
Total expensesTotal Expenses$16.0M
Pretax incomePretax Income-$15.8M

Learn while you research

Academy chapters picked for Greenwich LifeSciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →